title: Linezolid-associated peripheral neuropathy.
abstract: Linezolid is the first drug in a new class of synthetic antimicrobials, the oxazolidinones, to be approved by the Food and Drug Administration. Linezolid is active against methicillin- and vancomycin-resistant gram-positive microorganisms. We describe 2 patients who developed peripheral neuropathy after prolonged treatment with linezolid. Linezolid-associated peripheral neuropathy has not been well documented. Most reported cases of linezolid-associated peripheral neuropathy have occurred in patients who took linezolid for a period longer than the recommended 28 or fewer days. Health care providers must be alert to the potential for serious adverse effects associated with linezolid use, including peripheral neuropathy.
authors.affiliation: Division of General Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA.
authors.forename: Jennifer P
authors.initials: JP
authors.lastname: Rho
authors.forename: Irene G
authors.initials: IG
authors.lastname: Sia
authors.forename: Brian A
authors.initials: BA
authors.lastname: Crum
authors.forename: Mark B
authors.initials: MB
authors.lastname: Dekutoski
authors.forename: Robert T
authors.initials: RT
authors.lastname: Trousdale
mesh_terms: D000081:Acetamides / Q000009:adverse effects*; D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000009:adverse effects*; D006801:Humans; D000069349:Linezolid; D008297:Male; D023303:Oxazolidinones / Q000009:adverse effects*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced*; D013530:Surgical Wound Infection
chemical_list: D000081:Acetamides; D000890:Anti-Infective Agents; D023303:Oxazolidinones; D000069349:Linezolid